April 23, 2009 - AutoPulse Adoption Expanding in Alberta INVESTOR CONTACT: A. Ernest WhitonChief Financial OfficerZOLL Medical Corporation+1 (978) 421-9655 MEDIA CONTACT: Diane EganZOLL Medical Corporation+1 (978) firstname.lastname@example.org ADOPTION OF ZOLL AUTOPULSE EXPANDS IN ALBERTA, CANADA Device Delivers Significant Advantages over Manual CPR in Hospitals and EMS April 23, 2009—CHELMSFORD, Mass.—ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced today that a growing number of hospitals and emergency service organizations in the oil and gas producing region of Northern Alberta, Canada, have installed the AutoPulse® Non-Invasive Cardiac Support Pump to treat sudden cardiac arrest (SCA) more effectively. These services include Queen Elizabeth II Hospital in Grande Prairie; Redwater Health Center in Redwater; Whitecourt Health Center and Associated Ambulance in Whitecourt; Fort McMurray Fire Department in Wood Buffalo; the Syncrude Canada Oil Complex, Muskwachees Ambulance in Hobbema; Lakeside EMS in Sylvan Lake; Specialty Medical Service in Rocky Mountain House; and Lethbridge College in Lethbridge, where the AutoPulse is used in paramedic training. According to Tany Yao, Chief Officer of Fort McMurray Fire Department (FMFD), located in the northern most corner of the province, “When we have brought patients to the hospital, the ICU and ER doctors have been impressed by the pressure and circulation of our patients that resulted from the use of this device. For our medics, AutoPulse is simple, not awkward to use, and convenient for taking patients into the ER without stopping chest compressions.” He added that Fort McMurray is located in the largest geographic municipality in Canada and has the longest transport times. FMFD has been using the AutoPulse for two to three years and currently has six units in service. The AutoPulse® Non-invasive Cardiac Support Pump is an automated, portable device with an easy-to-use, load-distributing LifeBand® that squeezes the entire chest, improving blood flow to the heart and brain during sudden cardiac arrest (SCA). The AutoPulse has been shown to improve survival to discharge in a study published in the Journal of the American Medical Association (JAMA)*. The AutoPulse offers a significant advantage over manual CPR because it moves more blood, more consistently, than is possible with human hands. AutoPulse delivers high-quality, uninterrupted chest compressions to maintain myocardial and cerebral perfusion. Additionally, it offers the benefit of freeing up rescuers to focus on other life-saving interventions. Health Canada, the equivalent to the U.S. Food and Drug Administration, approved the AutoPulse for use in Canada in November 2003. Currently, it is in use by several EMS agencies in the country. To date, more than 4,000 AutoPulse units have been deployed in hospitals and emergency services worldwide. About Sudden Cardiac Arrest SCA claims more than 1 million lives each year worldwide. It is the leading cause of unexpected death in the world and strikes without warning. Currently, only about 5 percent of victims survive; 95 percent will die from SCA. SCA is an abrupt disruption of the heart’s function, which causes a lack of blood flow to vital organs. About ZOLL Medical Corporation ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, hypothermia, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help® and See-Thru CPR®, that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information. ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. During 2008 ZOLL marked the 25th anniversary of the company’s resuscitation product development. For more information, visit www.zoll.com. Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on February 6, 2009. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements. Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, LifeBand, Real CPR Help, and See-Thru CPR are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.